OTC · Biotechnology

IMV Inc. (IMVIQ) Stock

$0.00 OTC: IMVIQ Healthcare

IMV Inc. is a biotechnology firm focused on developing cancer treatments, currently in the clinical trial phase.

Valuation

MetricValue
Price$0.00
Market Cap$117
P/E Ratio-0.18
P/B Ratio-1.01
P/S Ratio0.00
EPS (TTM)$-4.55
52-Week High$5.00
52-Week Low—
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE542.86%
ROA-122.58%
ROCE-180.11%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-4.14
Current Ratio3.11

Annual Financials (USD)

Metric20182019202020212022
Revenue$0$0$0$0$0
Operating Profit$-15.0M$-20.0M$-28.0M$-36.0M$-39.0M
Net Profit$-16.0M$-21.0M$-27.0M$-37.0M$-38.0M
EPS$-3.68$-4.22$-4.10$-4.93$-4.55
Op Margin-25550.1%-45144.8%-1170888.1%——

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$17.0M$17.0M$46.0M$50.0M$31.0M
Total Liabilities$14.0M$12.0M$15.0M$29.0M$38.0M
Cash$11.0M$11.0M$36.0M$39.0M$21.0M
Borrowings$7.0M$8.0M$8.0M$20.0M$29.0M

Latest News

Sandvik to provide automated fleet for Viscaria copper mine restart Mining Technology · Aug 6, 2026 Clarivate Insider Sold Shares Worth $4,829,859, According to a Recent SEC Filing MT Newswires · Aug 6, 2026 Form 8.3 Business Wire · Aug 6, 2026 El Pollo Loco Holdings Insider Sold Shares Worth $1,686,600, According to a Recent SEC Filing MT Newswires · Aug 6, 2026 Possible Strait of Hormuz deal, Israeli soldiers killed in Lebanon and other news in the Mideast Associated Press · Aug 6, 2026

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-13.0M$-21.0M$-23.0M$-32.0M$-33.0M
Investing Cash Flow$-3.0M$-1.0M$-1.0M$-3.0M$-2.0M
Financing Cash Flow$14.0M$21.0M$49.0M$36.0M$17.0M
Net Cash Flow$0$-1.0M$25.0M$2.0M$-17.0M
Free Cash Flow$-14.0M$-21.0M$-24.0M$-33.0M$-34.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-0.47
FCF Yield-369.06%
Quick Ratio2.93
Interest Coverage-78.83
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALNAQAllena Pharmaceuticals, Inc. $0.00 — — $122 0.00%
BUGVFPrimo Nutraceuticals Inc. $0.00 — 0.00 $26 0.00%
GRYNGreen Hygienics Holdings Inc. $0.00 — 0.00 $44 0.00%
INDRIndie Ranch Media, Inc. $0.00 — — $132 0.00%
LHRPLifeHOUSE Holdings, LLC $0.00 — — $34 0.00%

About IMV Inc.

IMV Inc. is a biotechnology firm focused on developing cancer treatments, currently in the clinical trial phase. It leverages its proprietary DPX immune-modulating technology platform to create a range of therapeutic candidates aimed at both solid and blood-related cancers. Its primary investigational therapy, maveropepimut-S, is an immunotherapy built on the DPX platform, designed to target cells that express survivin. This compound is currently undergoing Phase II clinical evaluations for conditions such as diffuse large B-cell lymphoma, ovarian cancer, as well as solid tumors of the bladder, liver, and those exhibiting high microsatellite instability (MSI-H). Additionally, maveropepimut-S is in Phase I trials for breast cancer. Other developments include DPX-SurMAGE, which is in Phase I trials for bladder cancer, along with candidates like DPX-COVID-19 and DPX-RSV, which are being explored for infectious diseases. Previously known as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018. Established in 2000, IMV Inc. maintains its headquarters in Dartmouth, Canada.

IMV Inc. (IMVIQ) stock trades at $0.00 with a market capitalization of $117. The stock is valued at a price-to-earnings (P/E) ratio of -0.18, price-to-book of -1.01, price-to-sales of 0.00.

On profitability, IMV Inc. generates a return on equity (ROE) of 542.86% — well above the market average, a sign of a high-quality business, return on capital employed of -180.11%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.imv-inc.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides